Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) saw strong trading volume on Thursday . 1,509,609 shares traded hands during trading, an increase of 26% from the previous session’s volume of 1,195,256 shares.The stock last traded at $4.97 and had previously closed at $4.92.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. Brean Capital reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Wednesday, June 15th. Jefferies Group reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Monday, April 4th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $10.35.

The firm’s market capitalization is $337.84 million. The firm has a 50-day moving average of $4.77 and a 200 day moving average of $4.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.05. The firm earned $2.50 million during the quarter, compared to analysts’ expectations of $3.27 million. During the same quarter last year, the firm earned ($0.15) earnings per share. The company’s quarterly revenue was up 908.1% on a year-over-year basis. Equities analysts predict that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.